You are viewing the comprehensive archive for articles tagged with "ai drug discovery." Our editorial team delivers timely artificial intelligence coverage, practical insights, and industry-focused analysis across the topics shaping how AI is built, funded, regulated, and adopted. This section brings together the most relevant news, research, and expert commentary to help you understand trends and make better technology decisions. Stay informed with AIstify to keep your perspective current and complete.
Jeff Bezos’s industrial AI startup Prometheus raised $12 billion at a $41 billion valuation, emerging from stealth to build AI for engineering and manufacturing.
OpenAI has introduced GPT-Rosalind, a specialized AI model for life sciences research. The system aims to accelerate drug discovery and biological analysis workflows.
AWS has launched Amazon Bio Discovery, an AI-powered platform that helps scientists design, test, and refine drugs faster using integrated models and lab workflows.
Novo Nordisk is teaming up with OpenAI to use AI in drug discovery and development, aiming to speed up treatments for obesity and diabetes.
Mantis Biotech is developing AI-powered digital twins to generate synthetic biomedical data and improve research across healthcare and life sciences.
Eli Lilly has signed a $2.75 billion deal with Insilico Medicine to commercialize AI-developed therapies globally.
A Sydney engineer used AI tools including ChatGPT and AlphaFold to help design a personalized mRNA cancer vaccine for his dog with help from university researchers. Early results show significant tumor shrinkage.
Utah launches an AI pilot for prescription renewals, letting algorithms handle routine medication management without physicians, highlighting regulatory and safety challenges.
AstraZeneca has signed a $555 million milestone-based partnership with Algen Biotechnologies to deploy AI and CRISPR gene-editing together for immunology drug discovery.